AbbVie (NYSE: ABBV) shares offer an above-average dividend yield of 4% at recent prices, but some cautious investors were turned off by earnings that fell by 58% to $2.3 billion in the first half of the year. Lucrative drug sales allowed AbbVie's operation to generate a whopping $23.5 billion in free cash flow over the past 12 months. With additional growth drivers like Epkinly and Vraylar pushing the company's needle, AbbVie should have no problem raising its dividend payout at a pace that exceeds inflation over the long run.